Another major challenge for the selection of the best targets for a CD4+ T-cell-based immunotherapy is to identify which of the immunogenic neo-epitopes are generated by the MHC class II processing machinery and displayed by the tumor cells for T-cell recognition. Here, HLA-C is linked to neoplasm.